Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12369756 | 0.82 | LMNA (0.58) | LMNASMN1; SMN2TRPM8AOC3KMT2A | |
| SCHEMBL12369738 | 0.81 | LMNA (0.66) | LMNASMN1; SMN2TRPM8AOC3KMT2A | |
| SCHEMBL2611130 | 0.80 | CHRNB2 (0.42) | SMN1; SMN2NOTUMKMT2APIK3CDRAB9A | |
| SCHEMBL18590281 | 0.78 | SMN1; SMN2 (0.54) | LMNASMN1; SMN2TRPM8AOC3CHRM2 | |
| SCHEMBL3585642 | 0.77 | PIK3CD (0.46) | NOTUMKMT2APIK3CDRAB9A | |
| SCHEMBL6872550 | 0.74 | LMNA (0.61) | LMNASMN1; SMN2AOC3RAB9A | |
| SCHEMBL3544012 | 0.74 | LMNA (0.71) | LMNASMN1; SMN2AOC3KMT2ARAB9A | |
| SCHEMBL18590309 | 0.73 | SMN1; SMN2 (0.48) | LMNASMN1; SMN2AOC3RAB9AL3MBTL1 | |
| SCHEMBL13892296 | 0.73 | SMN1; SMN2 (0.54) | LMNASMN1; SMN2TRPM8KMT2ACHRM2 | |
| SCHEMBL2644386 | 0.73 | SMN1; SMN2 (0.69) | LMNASMN1; SMN2TRPM8AOC3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3257851-B1 | SALT FORM AND CRYSTAL FORM OF 1,2,5 THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE | JIANGSU KANION PHARMACEUTICAL CO LTD (CN) | 2020-09-09 | — | — | EP | disclosed |
| US-10227339-B2 | Salt form and crystal form of 1,2,5-thiadiazolidin-1,1-dioxide, preparation method thereof and intermediate | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2019-03-12 | — | — | US | disclosed |
| US-20180141940-A1 | SALT FORM AND CRYSTAL FORM OF 1,2,5-THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE | JIANGSU KANION PARMACEUTICAL CO. LTD (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20180141940-A1 | SALT FORM AND CRYSTAL FORM OF 1,2,5-THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE | JIANGSU KANION PARMACEUTICAL CO. LTD (CN) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227339-B2 | Salt form and crystal form of 1,2,5-thiadiazolidin-1,1-dioxide, preparation method thereof and intermediate | SPIN1, SULT1A1, NAP1L1 | LMNA 3676/4885SMN1; SMN2 3489/4885TRPM8 1463/4885 |
| US-20180141940-A1 | SALT FORM AND CRYSTAL FORM OF 1,2,5-THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE | SPIN1, SULT1A1, NAP1L1 | LMNA 3676/4885SMN1; SMN2 3489/4885TRPM8 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.